1887
  1. Home
  2. Eurosurveillance
  3. Volume 25, Issue 45, 12/Nov/2020
  4. Article
Rapid communication Open Access
Like 0
Download

Abstract

We analysed factors associated with neutralising antibody levels in 330 convalescent plasma donors. Women and younger donors were more likely not to have measurable neutralising antibodies, while higher antibody levels were observed in men, in older donors and in those who had been hospitalised. These data will be of value in the timely recruitment of convalescent plasma donors most likely to have high levels of neutralising antibodies for ongoing studies investigating its effectiveness.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2020.25.45.2001754
2020-11-12
2024-11-15
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2020.25.45.2001754
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/25/45/eurosurv-25-45-2.html?itemId=/content/10.2807/1560-7917.ES.2020.25.45.2001754&mimeType=html&fmt=ahah

References

  1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506.  https://doi.org/10.1016/S0140-6736(20)30183-5  PMID: 31986264 
  2. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78.  https://doi.org/10.1016/S0140-6736(20)31022-9  PMID: 32423584 
  3. Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396(10249):467-78.  https://doi.org/10.1016/S0140-6736(20)31604-4  PMID: 32702298 
  4. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117(17):9490-6.  https://doi.org/10.1073/pnas.2004168117  PMID: 32253318 
  5. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582-9.  https://doi.org/10.1001/jama.2020.4783  PMID: 32219428 
  6. Zhang L, Pang R, Xue X, Bao J, Ye S, Dai Y, et al. Anti-SARS-CoV-2 virus antibody levels in convalescent plasma of six donors who have recovered from COVID-19. Aging (Albany NY). 2020;12(8):6536-42.  https://doi.org/10.18632/aging.103102  PMID: 32320384 
  7. Ibrahim D, Dulipsingh L, Zapatka L, Eadie R, Crowell R, Williams K, et al. Factors associated with good patient outcomes following convalescent plasma in COVID-19: A prospective phase II clinical trial. medRxiv 2020. Available from: https://doi.org/ https://doi.org/10.1101/2020.08.27.20183293 
  8. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460-70.  https://doi.org/10.1001/jama.2020.10044  PMID: 32492084 
  9. Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, Ruiz-Antoran B, Malo de Molina R, Torres F, et al. Convalescent plasma for COVID-19: A multicenter, randomized clinical trial. medRxiv 2020. Available from: https://doi.org/ https://doi.org/10.1101/ 2020.08.26.20182444v3 
  10. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al. Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study. Nat Med. 2020.  https://doi.org/10.1038/s41591-020-1088-9  PMID: 32934372 
  11. Joyner M, Senefeld JW, Klassen SA, Mills JR, Johnson PW, Theel ES, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv 2020. Available from: https://doi.org/ https://doi.org/10.1101/2020.08.12.20169359 
  12. Harvala H, Mehew J, Robb ML, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma treatment for SARS-CoV-2 infection: analysis of the first 436 donors in England, 22 April to 12 May 2020. Euro Surveill. 2020;25(28):2001260.  https://doi.org/10.2807/1560-7917.ES.2020.25.28.2001260  PMID: 32700670 
  13. Harvala H, Robb ML, Watkins N, Ijaz S, Dicks S, Patel M, et al. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels. medRxiv 2020. Available from: https://doi.org/ https://doi.org/10.1101/ 2020.05.20.20091694v1 
  14. Consolidated Analysis Centers, Inc. (CACI). ACORN categorisations of deprivation in the UK based on geodemographic segmentation of the UK’s population. London: CACI; 2014. Available from: https://acorn.caci.co.uk/downloads/Acorn-User-guide.pdf
  15. Gallian P, Pastorino B, Morel P, Chiaroni J, Ninove L, de Lamballerie X. Lower prevalence of antibodies neutralizing SARS-CoV-2 in group O French blood donors. Antiviral Res. 2020;181:104880.  https://doi.org/10.1016/j.antiviral.2020.104880  PMID: 32679056 
  16. Fan Q, Zhang W, Li B, Li DJ, Zhang J, Zhao F. Association between ABO blood group system and COVID-19 susceptibility in Wuhan. Front Cell Infect Microbiol. 2020;10:404.  https://doi.org/10.3389/fcimb.2020.00404  PMID: 32793517 
  17. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, et al. Genomewide association study of severe COVID-19 with respiratory failure. N Engl J Med. 2020;383(16):1522-34.  https://doi.org/10.1056/NEJMoa2020283  PMID: 32558485 
  18. Klein S, Pekosz A, Park HS, Ursin R, Shapiro J, Benner S, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. medRxiv 2020. Available from: https://www.medrxiv.org/content/10.1101/2020.06.26.20139063v1
  19. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442-7.  https://doi.org/10.1038/s41577-020-0348-8  PMID: 32528136 
Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Jennifer+Mehew&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Mehew Jennifer</a>, <a href="/search?value1=Rachel+Johnson&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Johnson Rachel</a>, <a href="/search?value1=David+Roberts&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Roberts David</a>, <a href="/search?value1=Heli+Harvala&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Harvala Heli</a></span>. Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels, England, 22 April to 12 May 2020. <a href="/content/ecdc">Euro Surveill.</a> 2020;25(45):pii=2001754. <a href="https://doi.org/10.2807/1560-7917.ES.2020.25.45.2001754" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2020.25.45.2001754</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 06 Oct 2020;&nbsp;&nbsp; <span class="generated">Accepted</span>: 09 Nov 2020 </span> </p>
/content/10.2807/1560-7917.ES.2020.25.45.2001754
/content/10.2807/1560-7917.ES.2020.25.45.2001754
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error